SGLT2i treatment during AKI and its association with major adverse kidney events by Luz Alcantar-Vallin, Luz Alcantar-Vallin, Jose J. Zaragoza, Bladimir Díaz-Villavicencio, Bladimir Díaz-Villavicencio, Karla Hernandez-Morales, Karla Hernandez-Morales, Jahir R. Camacho-Guerrero, Jahir R. Camacho-Guerrero, Miguel A. Perez-Venegas, Miguel A. Perez-Venegas, Edgar J. Carmona-Morales, Edgar J. Carmona-Morales, Alexa N. Oseguera-Gonzalez, Alexa N. Oseguera-Gonzalez, Cesar Murguia-Soto, Cesar Murguia-Soto, Gael Chávez-Alonso, José M. Arredondo-Dubois, Carlos E. Orozco-Chan, Juan A. Gómez-Fregoso, Francisco G. Rodríguez-García, Guillermo Navarro-Blackaller, Guillermo Navarro-Blackaller, Ramón Medina-González, Alejandro Martínez Gallardo-González, Alejandro Martínez Gallardo-González, Gabriela J. Abundis-Mora, Olynka Vega-Vega, Guillermo García-García, Jonathan S. Chávez-Iñiguez, Jonathan S. Chávez-Iñiguez

Connect to this object online.